WVT078A
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$83,960
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $83,960 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $83,960 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I, OPEN-LABEL, MULTICENTER, STUDY OF WVT078 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Novartis Pharmaceuticals Corporation | $83,960 | 0 |
Top Doctors Receiving Payments for WVT078A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $83,960 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $83,960
- Total Doctors 0
- Transactions 3
About WVT078A
WVT078A is a biological associated with $83,960 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $83,960 was paid across 3 transactions to 0 doctors.
The most common payment nature for WVT078A is "Unspecified" ($83,960, 100.0% of total).
WVT078A is associated with 1 research study, including "A PHASE I, OPEN-LABEL, MULTICENTER, STUDY OF WVT078 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA" ($83,960).